Abstract:Mahmoud A Younis, 1, 2 Hideyoshi Harashima 1 1 Laboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan; 2 Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt Correspondence: Hideyoshi Harashima, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan, Email Mahmoud A Younis, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt, Email Hepatocellular carcinoma (HCC) is the dominant type of liver cancers and is one of the deadliest health threats globally. The conventional therapeutic options for HCC are hampered by low efficiency and intolerable side effects. Gene therapy, however, now offers hope for the treatment of many disorders previously considered incurable, and gene therapy is beginning to address many of the shortcomings of conventional therapies. Herein, we summarize the involvement of genes in the pathogenesis and prognosis of HCC, with a special focus on dysregulated signaling pathways, genes involved in immune evasion, and non-coding RNAs as novel two-edged players, which collectively offer potential targets for the gene therapy of HCC. Herein, the opportunities and challenges of HCC gene therapy are discussed. These include innovative therapies such as genome editing and cell therapies. Moreover, advanced gene delivery technologies that recruit nanomedicines for use in gene therapy for HCC are highlighted. Finally, suggestions are offered for improved clinical translation and future directions in this area of endeavor. Keywords: hepatocellular carcinoma, gene therapy, personalized medicine, nanomedicines, clinical translation Hepatocellular carcinoma (HCC), the most common type of liver cancers, is a serious life-terminating threat and a major cause of death across the globe. According to the American Cancer Society, more than 800,000 new cases are diagnosed annually, and the death toll exceeds 700,000 cases every year. The incidence rates have tripled over the past four decades, while the mortality rates have doubled. 1 According to the latest guidelines from both the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), surgical resection is adopted as the first choice in the treatment of localized HCC in the absence of liver cirrhosis. Neoadjuvant therapy using Atezolizumab and Bevacizumab as well as immune checkpoint inhibitors can be considered before and after surgery to reduce the risk of postoperative recurrence. For patients with non-resectable tumors, local ablative therapies such as thermal ablation or radiation segmentectomy are recommended. For ineligible patients, chemotherapy with multiple kinase inhibitors (eg Sorafenib) remains the available therapeutic option. 2,3 Unfortunately, most HCC cases are diagnosed at advanced stages or along with viral hepatitis or liver cirrhosis, which collectively limit the applicability of the above choices. Moreover, systemic chemotherapy is hampered by serious side effects as well as the emergence of chemoresistance, leaving the survival rates not being improved significantly over the past decades. 4 On the other hand, liver transplantation is not an affordable choice for a substantial proportion of patients, especially in the developing, low-income countries. 5 Recent interest in innovative therapeutic approaches such as molecular medicine and cell therapies has grown thanks to breakthroughs in molecular biology and the relevant tools. Gene therapy has emerged to address the shortcomings of conventional therapies. 6 Kymriah ® was the first FDA-approved gene therapy for the treatment of blood tumors in 2017, 7 followed by Luxturna ® for the treatment of inherited blindness in the same year. 8 Subsequently, Onpattro ® appeared in 2018 as the first FDA-approved RNA drug for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR). 9 The gene-therapy revolution has continued with the evolution of messenger RNA (mRNA) vaccines in 2020, 10 in parallel with significant advancements in genome editing technologies that resulted in the Nobel prize in chemistry for Jennifer Doudna and Emmanuelle Charpentier who pioneered the CRISPR-Cas9 modality. 11 Meanwhile, advancements in nucleic acid chemistry have enabled the design of chemically modified nucleosides that have promoted higher levels of stability and have lowered the innate immunogenicity of RNA therapeutics, which is an achievement that was acknowledged by the 2023 Nobel prize in physiology or medicine for Katalin Karikó and Drew Weissman. 12 The present article sheds light on th -Abstract Truncated-

CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma

Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management

Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer

CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy

CRISPR, CAR-T, and NK: Current applications and future perspectives

Harnessing the evolving CRISPR/Cas9 for precision oncology

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy

CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy

Targeting Cancer with CRISPR/Cas9-Based Therapy

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

The role of the CRISPR‐Cas system in cancer drug development: Mechanisms of action and therapy

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma

Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine

The Potential Revolution of Cancer Treatment with CRISPR Technology

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

CRISPR-Cas9 Genome Editing for Cancer Immunotherapy: Opportunities and Challenges.

Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction

Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review